"Treatment of metastatic renal cell carcinoma (mRCC) was once limited to the treatment with interleukin-2 and interferon (INF)-α. Major efforts in understanding the molecular mechanism of the disease have led to a better understanding of the molecular biology of renal cancer, and this has subsequently led to the development of a multitude of drugs acting on the vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) pathway. The registration of many of these new drugs (sunitinib, sorafenib, axitinib, lapatinib, pazopanib, bevacizumab, everolimus or temsirolimus) has led to the situation where it is increasingly difficult to show improvement of overall survival (OS) with even newer drugs, and to define the best sequence of this various compounds in patients with mRCC." Read the complete ESMO journal club article here.
Study mentioned: Delea TE, et al. Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma. Br J Cancer. 2012 Sep 25;107(7):1059-68. PMID: 22935581
No comments:
Post a Comment